MiMedx Group (NASDAQ:MDXG - Get Free Report)'s stock had its "overweight" rating reissued by investment analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They currently have a $8.00 price target on the stock. Cantor Fitzgerald's price objective points to a potential upside of 151.57% from the stock's previous close.
MDXG has been the topic of a number of other research reports. Seaport Research Partners cut shares of MiMedx Group to a "neutral" rating in a research report on Monday, August 17th. Craig Hallum lifted their price objective on MiMedx Group from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Thursday, August 27th. Wall Street Zen raised MiMedx Group from a "sell" rating to a "hold" rating in a research report on Saturday, August 29th. Mizuho set a $7.00 price objective on MiMedx Group in a research note on Thursday, October 29th. Finally, Raymond James Financial set a $8.00 target price on MiMedx Group in a research report on Monday, August 17th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $8.14.
Read Our Latest Analysis on MDXG
MiMedx Group Stock Performance
NASDAQ:MDXG opened at $3.18 on Tuesday. The firm's fifty day moving average is $4.23 and its 200-day moving average is $4.17. MiMedx Group has a 52 week low of $3.03 and a 52 week high of $7.51. The firm has a market cap of $464.06 million, a P/E ratio of -24.46 and a beta of 1.17.
MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($0.01) earnings per share for the quarter. MiMedx Group had a positive return on equity of 2.39% and a negative net margin of 6.32%. The firm had revenue of $62.28 million for the quarter, compared to analyst estimates of $68.56 million. As a group, sell-side analysts anticipate that MiMedx Group will post -0.08 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of MDXG. Parallel Advisors LLC boosted its stake in MiMedx Group by 2,248.3% during the third quarter. Parallel Advisors LLC now owns 7,632 shares of the company's stock worth $36,000 after acquiring an additional 7,307 shares in the last quarter. GAMMA Investing LLC grew its holdings in MiMedx Group by 2,422.5% in the third quarter. GAMMA Investing LLC now owns 7,719 shares of the company's stock worth $36,000 after purchasing an additional 7,413 shares during the period. Jump Financial LLC bought a new stake in MiMedx Group in the third quarter valued at $47,000. Sunbelt Securities Inc. bought a new stake in MiMedx Group in the first quarter valued at $42,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of MiMedx Group during the second quarter valued at about $45,000. Institutional investors and hedge funds own 79.15% of the company's stock.
MiMedx Group Company Profile
(
Get Free Report)
MiMedx Group is a healthcare company that develops and markets biologic products made from donated human placental tissue. Its offerings include amniotic membrane and umbilical cord allografts for use in wound care and surgical procedures. The company's products include EpiFix, used in the management of certain chronic wounds, and other tissue-based products for wound and surgical applications. MiMedx uses its proprietary PURION processing method to prepare donated tissue for clinical use. Founded in 2008 and headquartered in Marietta, Georgia, MiMedx primarily serves healthcare providers in the United States, with sales in select international markets.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.